Annaliesa Anderson

Dr. Anderson is an Observer on our Science & Technology Committee. She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacterial Vaccines, within the Vaccine Research and Development Unit at Pfizer Inc. In addition to this role she is the Chief Scientific Officer for the Hospital Business Unit. Her responsibilities include infectious disease vaccine research and development and providing oversite for Pfizer’s anti-infective and diagnostic strategies. Dr. Anderson’s experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus, Clostridium difficile and Group B Streptococcus. In these roles, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept, and vaccine licensure.

Prior to joining Pfizer, Dr. Anderson worked at Merck Research Laboratories in Rahway, NJ, where she founded Merck’s prokaryotic bio-combinational engineering laboratory and initiated a bacterial vaccine program at Merck in 2000. She went on to lead the Microbial vaccines research department. In 2007, Dr. Anderson joined Wyeth in Pearl River, NY, to direct the bacterial vaccine research efforts in the Early Phase Vaccine Programs group. With acquisition of Wyeth by Pfizer in 2009, Dr. Anderson and her team continued in their same role with the Vaccine Research and Development Unit.

Dr. Anderson earned her doctorate in biological sciences at the University of Warwick, England, in the field of microbial ecology and then completed two post-doctoral fellowships.